Envista (NYSE:NVST) Upgraded to “Hold” at BMO Capital Markets

BMO Capital Markets upgraded shares of Envista (NYSE:NVST) to a hold rating in a report published on Wednesday,Zacks.com reports.

NVST has been the subject of a number of other reports. Citigroup began coverage on Envista in a research report on Wednesday, April 15th. They issued a “neutral” rating and a $29.00 price target for the company. Weiss Ratings downgraded shares of Envista from a “hold (c)” rating to a “hold (c-)” rating in a report on Monday, May 11th. Robert W. Baird increased their target price on shares of Envista from $30.00 to $31.00 and gave the company an “outperform” rating in a report on Thursday, May 7th. Evercore reissued an “outperform” rating and set a $33.00 price target on shares of Envista in a research report on Thursday, May 7th. Finally, Zacks Research cut shares of Envista from a “strong-buy” rating to a “hold” rating in a report on Monday, April 6th. Six analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $28.54.

Envista Price Performance

NVST stock opened at $25.75 on Wednesday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.06 and a current ratio of 2.44. The business has a 50-day simple moving average of $24.84 and a two-hundred day simple moving average of $25.42. The company has a market capitalization of $4.19 billion, a P/E ratio of 62.80, a price-to-earnings-growth ratio of 1.46 and a beta of 0.86. Envista has a 52-week low of $18.77 and a 52-week high of $30.42.

Envista (NYSE:NVST) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.36 EPS for the quarter, topping the consensus estimate of $0.31 by $0.05. Envista had a return on equity of 7.11% and a net margin of 2.41%.The firm had revenue of $705.50 million during the quarter, compared to the consensus estimate of $680.03 million. During the same period in the prior year, the business posted $0.24 earnings per share. The company’s quarterly revenue was up 14.4% compared to the same quarter last year. Envista has set its FY 2026 guidance at 1.350-1.450 EPS. Research analysts expect that Envista will post 1.42 EPS for the current fiscal year.

Institutional Investors Weigh In On Envista

A number of hedge funds have recently made changes to their positions in NVST. Caitong International Asset Management Co. Ltd grew its position in Envista by 16,711.1% during the third quarter. Caitong International Asset Management Co. Ltd now owns 1,513 shares of the company’s stock valued at $31,000 after buying an additional 1,504 shares during the period. Allworth Financial LP increased its holdings in Envista by 75.4% during the fourth quarter. Allworth Financial LP now owns 1,805 shares of the company’s stock worth $39,000 after buying an additional 776 shares during the last quarter. UMB Bank n.a. raised its position in Envista by 46.1% in the fourth quarter. UMB Bank n.a. now owns 2,017 shares of the company’s stock worth $44,000 after acquiring an additional 636 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Envista by 73.1% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,248 shares of the company’s stock worth $44,000 after acquiring an additional 949 shares during the period. Finally, IFP Advisors Inc boosted its stake in Envista by 102.9% in the fourth quarter. IFP Advisors Inc now owns 2,112 shares of the company’s stock valued at $46,000 after acquiring an additional 1,071 shares during the last quarter.

About Envista

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.